Luminex is developing a new version of its xTAG PCR chemistry that it believes will improve the ease of use of its technology while maintaining its high-multiplex and high-throughput capabilities.

The Austin, Texas-based company intends to apply the new chemistry to its US Food and Drug Administration-approved Respiratory Viral Panel, with plans to commence clinical trials on the updated assay in 2014 and submit it to the FDA the following year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.